23andMe Sells Gene-Testing Business to DNA Drug Maker Regeneron - Bloomberg


Bankrupt 23andMe sold its extensive DNA database to Regeneron Pharmaceuticals for $256 million, ensuring data privacy under Regeneron's commitment to existing customer policies.
AI Summary available โ€” skim the key points instantly. Show AI Generated Summary
Show AI Generated Summary

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.

The sale comes after a wave of customers and government officials demanded that 23andMe protect the genetic data it had built up over the years by collecting saliva samples from customers. Regeneron pledged to comply with 23andMeโ€™s privacy policy, which allows customers to have their personal information deleted upon request.

Was this article displayed correctly? Not happy with what you see?

Tabs Reminder: Tabs piling up in your browser? Set a reminder for them, close them and get notified at the right time.

Try our Chrome extension today!


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device


Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more

Facebook

Save articles to reading lists
and access them on any device